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Abstract
Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic cell transplantation and is largely
mediated by activated donor lymphocytes. Lymphotoxin (LT)-a is expressed by subsets of activated T and B cells, and
studies in preclinical models demonstrated that targeted depletion of these cells with a mouse anti-LT-a monoclonal
antibody (mAb) was efficacious in inhibiting inflammation and autoimmune disease. Here we demonstrate that LT-a is also
upregulated on activated human donor lymphocytes in a xenogeneic model of GVHD and targeted depletion of these
donor cells ameliorated GVHD. A depleting humanized anti-LT-a mAb, designated MLTA3698A, was generated that
specifically binds to LT-a in both the soluble and membrane-bound forms, and elicits antibody-dependent cellular
cytotoxicity (ADCC) activity in vitro. Using a human peripheral blood mononuclear cell transplanted SCID (Hu-SCID) mouse
model of GVHD, the anti-human LT-a mAb specifically depleted activated LT-expressing human donor T and B cells,
resulting in prolonged survival of the mice. A mutation in the Fc region, rendering the mAb incapable of mediating ADCC,
abolished all in vitro and in vivo effects. These data support a role for using a depleting anti-LT-a antibody in treating
immune diseases such as GVHD and autoimmune diseases.
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Introduction
Graft-versus-host disease (GVHD) is a complex immune disease
underlying the morbidity and mortality associated with transplan-
tation of hematopoietic stem cells into allogeneic recipients [1,2,3].
Induction of either acute or chronic GVHD occurs when
transferred alloreactive donor T cells respond to antigens
expressed on host tissues. The initial phase of acute GVHD
development is mediated by the proinflammatory environment
created by the tissue damage resulting from the conditioning
regimen, including total body irradiation and chemotherapy. The
release of proinflammatory cytokines, such as IL-1, IL-8 and TNF-
a, triggers a cascade of inflammatory events including the
activation and maturation of host antigen-presenting cells (APCs)
that in turn present host major or minor histocompatibility antigen
disparate proteins as complexes to donor T cells. These
alloreactive T cells are the critical mediators of GVHD, secreting
inflammatory cytokines (e.g. TNF-a, IFN-c, IL-2) and cytolytic
mediators, ultimately leading to the destruction of host organs,
primarily the skin, GI tract and liver [2].
Chronic GVHD represents a multi-organ syndrome that shares
many clinical manifestations with autoimmune diseases [4,5].
While chronic GVHD is a major cause of morbidity and mortality
in long-term survivors of allogeneic hematopoietic stem cell
transplantation, the pathophysiology of chronic GVHD is poorly
understood. As in acute GVHD, effector T cells and APCs play
important roles. Additionally, B cells are also speculated to have a
role, through direct cellular cytotoxicity by alloantibodies or as
functional APCs capable of activating and expanding alloreactive
T cells [5]. In chronic GVHD, alloantibody levels correlate with
disease development [6], B cell-activating factor (BAFF) levels are
high, and B cells with activated memory phenotype are present in
greater numbers while naı ¨ve B cell numbers are reduced [7].
In clinical practice, standard first-line therapy against acute GVHD
consists of corticosteroid treatment, as these agents are lympholytic and
inhibit inflammatory cytokine cascades [8]. However, a significant
patient population develops steroid-refractory/resistant GVHD that is
associated with high morbidity and mortality [3,8]. As primary
response to first-line treatment is predictive of long-term survival, the
lack of universally effective front-line therapy has driven the search for
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involved in acute GVHD. Based on the roles of cellular effectors and
soluble inflammatory mediators, biologics including monoclonal
antibodies (mAbs) and fusion proteins have been evaluated as
therapeutics against acute GVHD. Cell surface markers expressed by
effector cells have been targetedw i t hm A b s .T h e s ei n c l u d eC D 2
(alefacept), CD3 (OKT3, visilizumab), CD25 (daclizumab, basilix-
imab, denileukin-difitox), CD52 (alemtuzumab), and CD147 (ABX-
CBL). Strategies targeting cytokines include anti-TNF-a mAb
(infliximab) and TNF receptor fusion proteins (etanercept) (reviewed
in [3,8]). While many of these strategies have shown at least some
promising activity as salvage treatments in GVHD, due to the broad
effects on the host immune system, patients are often still at risk for
opportunistic infections or may develop lymphoproliferative disorders
or reoccurrence of leukemia.
Therefore, more selective therapeutic strategies targeting
activated pathogenic cells directly involved in GVHD may
improve the net clinical benefit.
Lymphotoxin (LT)- a, is a TNF-superfamily member and exists
as a soluble LT-a3 homotrimer that binds TNF receptors (TNFR),
or complexed with LT-b as a heterotrimer, LT-a1b2, on the cell
surface that binds to its cognate receptor LT-bR. The role of LT
in the immune response has been well characterized and is crucial
for the development and orchestration of robust immune
responses [9]. Surface expression of LT-a is restricted to subsets
of T and B cells. Activated CD4
+ Th subsets Th1 and Th17, but
not Th2, express surface LT [10,11] as do CD8
+ T cells and B
cells [12,13]. These cell types have all been implicated in the
pathogenesis of GVHD. We recently demonstrated efficacy with a
depleting anti-mouse LT-a mAb in mouse models of rheumatoid
arthritis (RA), experimental autoimmune encephalomyelitis (EAE)
and delayed-type hypersensitivity (DTH) [10]. In these studies, the
Fc-dependent efficacy achieved with anti-LT-a treatment resulted
in depletion of Th1 and Th17 cells, but not Th2.
The demonstrated efficacy of the depletion mechanism in
inhibiting T cell-mediated diseases in mouse inflammatory models
led us to look for mAbs directed against human LT-a with similar
properties. We describe here that a humanized anti-LT-a mAb
depleted activated T and B cells and increased survival in
xenogeneic human T cell-dependent peripheral blood mononu-
clear cell (PBMC) transplanted SCID (Hu-SCID) mouse model of
GVHD, whereas an Fc-effectorless mutant version of the antibody
did not. These data support a role for using a depleting anti-LT-a
antibody for eliminating pathogenic T and/or B cells in human
inflammatory and autoimmune diseases.
Materials and Methods
Ethics Statements
Leukopac or blood from healthy human donors was obtained
after written informed consent was provided and ethical approval
granted from the Western Institutional Review Board.
All animals used in this study were housed and maintained at
Genentech in accordance with American Association of Labora-
tory Animal Care guidelines. All experimental studies were
conducted under protocols (#06-1535, #06-0967B and all
subletters) approved by the Institutional Animal Care and Use
Committee of Genentech Lab Animal Research in an AAALACi-
accredited facility in accordance with the Guide for the Care and
Use of Laboratory Animals and applicable laws and regulations.
Reagents
A fully humanized anti-LT-a human IgG1 mAb, designated
MLTA3698A, was derived from a mouse anti-human LT-a
hybridoma mAb. The LT-a-specific Fc-mutant antibody (desig-
nated anti-LT-a-FcMT) that abolishes FccR binding was made as
previously described [10]. Human LT-bR.Ig, TNFRII.Ig, CTLA-
4.Ig and isotype-IgG1 have been previously described [10,14].
Surface plasmon resonance analysis by BIACORE
TM
Surface plasmon resonance measurements on a Biacore 3000
instrument was used to characterize the interaction of LT-a3o r
LT-a1b2 with anti-LT-a MLTA3698A. For IgG kinetic measure-
ments, amine chemistry was used to covalently immobilize 8,000
RU of goat F(ab9)2 anti-human Fc polyclonal antibody (Jackson
ImmunoResearch Laboratories) to 4 flow cells of a CM5 sensor
chip. After blocking unreacted sites with 1 M ethanolamine-HCl
pH 8, anti-LT-a MLTA3698A IgG was captured (100-500 RU)
on the anti-Fc surface by injection of 7 mL of 0.5 mg/mL antibody
at a flow rate of 10 mL/min. Solutions of recombinant LT-a3 (0,
50, and 100 nM) or LT-a1b2 (R&D Systems; 0, 200, 400, and
800 nM) were injected over the captured antibody and reference
flow cells. Injections of 60 mL were used and dissociation was
monitored for 20 minutes. Regeneration between samples was
done using 80 mL injections of 10 mM glycine, pH 1.5. Data were
analyzed according to a 1:1 binding model, after subtraction of
any reference cell signal, using BIAEval 3.1 to calculate kinetics
constants.
Binding and competitive blocking ELISA
Human LT-a1b2 and LT-a3 ELISA binding assays were
performed by coating microtiter wells overnight with 0.5–1 mg/ml
human LT-a1b2 or LT-a3 (R&D Systems), blocking with PBS
containing 5 mg/ml bovine serum albumin, followed by incuba-
tion with purified or biotinylated anti-LT-a mAb, or LT-bRo r
TNFRII IgG fusion proteins. Detection was with streptavidin-
horseradish peroxidase (SA-HRP) (Sigma) or horseradish perox-
idase conjugated goat F(ab9)2 anti-human Fc polyclonal antibody
(Jackson ImmunoResearch Laboratories) followed by tetramethyl-
benzidine. After the reaction was stopped with 1 M phosphoric
acid, absorbances were read at 450 nm with a reference
wavelength of 650 nm.
For competitive blocking ELISAs, recombinant LT-a3 or LT-
a1b2 was labeled with biotin (Pierce, Thermo Scientific).
Recombinant TNFRII.Ig and LT-bR.Ig were labeled using
SULFO-TAG NHS-ester (Meso Scale Discovery). Test molecules
were serially diluted, then biotinylated LT-a3 or LT-a1b2 added
and incubated for two hr. Test molecule/biotinylated anti-LT-a
mixtures were then added to streptavidin coated 96-well microtiter
plates and allowed to bind for 30 min. After washing, SULFO-
TAG TNFRII.Ig or LT-bR.Ig protein was added to the
TNFRII.Ig or anti-LT-a/LT-a3 or LT-bR or anti-LT-a/LT-
a1b2 binding pair titrations, respectively, and allowed to bind for
30 min. After washing and addition of Read Buffer T (Meso Scale
Discovery), plates were immediately read on an MA6000
SECTOR
TM Imager (Meso Scale Discovery).
ADCC
ADCC was performed as previously described [10]. Briefly, NK
cells were isolated from human PBMC using human NK Cell
Isolation Kit (Miltenyi Biotec). Target cells were either 293-hLT-
ab cells (Young 2010) or CD4
+ T cells purified from PBMC
(CD4
+ T Cell Isolation Kit, Miltenyi Biotec) stimulated in vitro for
two days on wells precoated with 5 mg/ml anti-CD3 mAb (BD
Biosciences) and in culture medium supplemented with 2 mg/ml
anti-CD28 mAb (BD Biosciences). In duplicates, 10,000 target
cells were pre-incubated with serially diluted mAbs for 30 min.
50,000 NK cells (E:T ratio of 5:1) were added and incubated for
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Detection Kit (LDH) (Roche) and percentage cytotoxicity
calculated.
FACS and immune cell in vitro stimulation
Antibodies used for staining were as follows: FITC, PE or
PerCP-conjugated anti-human CD4, CD8, CD19, CD25,
CD45RO, CD56, CD69 and HLA-DR were purchased from
BD Biosciences. Staining for surface LT-a1b2 was performed
using anti-LT-a MLTA3698A or LT.3F12 mAb [15], anti-LT-a-
FcMT or LT-bR.Ig [16]; all were Alexa-647-conjugated using
Alexa Fluor 647 Protein Labeling Kit (Invitrogen). For detection of
surface LT-a1b2 in animals treated with anti-LT-a mAb, staining
was performed using the non-cross blocking anti-LT-a antibody
LT.3F12 mAb which was shown to co-stain in the presence of
MLTA3698A [15]. Leukopacs or blood from healthy donors was
obtained after informed consent was provided and ethical
approval granted from the Western Institutional Review Board.
To track transferred human donor cells in the HuSCID model of
GVHD and monitor cell expansion, donor cells were labeled with
carboxyfluorescein succinimidyl ester (CFSE) cell tracer, using
standard labeling procedures. Samples were acquired on a
FACSCalibur flow cytometer using CellQuest Pro v5.1.1 software
(Tree Star, Inc.). For determination of absolute cell numbers,
CaliBRITE APC Beads (BD Biosciences) were added before
analyzing samples by flow cytometry, and total cell numbers were
determined according to manufacturer’s instructions. For T cell
activation, human PBMCs were cultured in complete DMEM
media (DMEM supplemented with 10% FBS, 2 mM glutamine,
2 mM 2-ME, 1 mM sodium pyruvate, 100 U/ml penicillin and
100 mg/ml streptomycin) in presence of 5 mg/ml anti-CD3 mAb
and 2 mg/ml anti-CD28 mAb for 2 days. For B cell activation,
PBMCs were cultured in complete DMEM media supplemented
with 100 ng/ml BAFF (R&D Systems) on microtiter plates
precoated with 1 mg/ml anti-IgM (Jackson ImmunoResearch) for
2 days. For monocyte activation, CD14
+ cells were isolated from
peripheral blood using MACS separation and cultured in
complete DMEM media supplemented with 1 mg/ml LPS
(InvivoGen) for 2 days. LT expression on all in vitro stimulated
human cells was detected using LT.3F12 mAb.
Hu-SCID mouse model of GVHD
Leukopacs from normal human donors were obtained from
Blood Centers of the Pacific (San Francisco, CA), and PBMCs
were isolated using standard methodologies. CFSE-labeled human
PBMCs were resuspended at a concentration of 50610
6 cells in
30 mL phosphate-buffered saline (PBS) and kept on ice prior to the
intrasplenic injection procedure. SCID/beige mice were pur-
chased from Charles River Laboratories (Hollister, CA) and
housed and maintained at Genentech in accordance with
American Association of Laboratory Animal Care guidelines. All
experimental studies were conducted under the approval of the
Institutional Animal Care and Use Committees of Genentech Lab
Animal Research. Twenty female 5–6 week old female SCID/
beige mice were sublethally irradiated with 350 rads using a
Cesium-137 source. Polymyxin B (110 mg/L) and neomycin
(1.1 g/L) were added to the drinking water for 7 days after
irradiation. Four hours after irradiation, the left flank of each
mouse was shaved and prepped with BetadineH (Purdue Pharma;
Stamford, CT) and 70% alcohol. The operation was performed
under anesthesia using aseptic surgical procedures. A 1-cm skin
incision was made just below the costal border, followed by an
incision of the abdominal wall and the peritoneum. The spleen
was carefully exposed and injected with 50610
6 CFSE-labeled
human PBMCs in 30 mL PBS. The incisions were closed in the
muscular layer and the skin with 5-O VicrylH sutures (Ethicon;
Somerville, NJ) and surgical staples, respectively. For lymphoid
cell phenotyping and determining expansion of human donor cells
based on CFSE profile, mice were sacrificed at days 1, 2, 3, and 4
post-transplantation, and spleens harvested. For survival studies,
each animal received 50610
6 unlabeled human PBMCs via i.v.
tail vein injection in 100 mL sterile PBS, four hours after
irradiation and dosing with experimental or control test articles.
Isotype control mAb, anti-LT-a, anti-LT-a-FcMT or CTLA-4.Ig,
were administered as i.p. injections at a dose of 12 mg/kg in
100 mL of saline, and treatment was continued with twice-weekly
injections. Survival of mice was monitored through day 28 and
data were plotted as Kaplan-Meier survival curves. Drug
bioavailability was confirmed by ELISA, and average serum drug
concentrations were 100–200 mg/ml at all time points examined
for all treatments.
Statistical analyses
Statistics were calculated using JMP version 6.0.2 software (SAS
Institute). We made comparisons for each pair with Student’s t
test; we made multiple comparisons with a single control with
Dunnett’s test; we compared survival using log-rank test. P
values,0.05 were considered significant. EC50 curves and values
were plotted and calculated using KaleidaGraph version 3.6
software (Synergy Software) using a 4-parameter curve fit formula:
M1+(M22M1)/(1+(M0/M4)‘M3); M1=minimum of curve,
M2=maximum of curve, M3=1, M4=estimated EC50.
Results
LT-a is expressed by activated lymphocytes
As activated T and B cells are key mediators of GVHD, we
determined if these subsets express surface LT-a in a xenogeneic
Hu-SCID model of GVHD. We initially assessed surface LT-a
expression on lymphocytic populations isolated from human
PBMC and activated in vitro (Figure 1). Surface LT-a is expressed
rapidly on T cells after activation [10,11] and is maintained
throughout cell-division in bulk CD4
+ T cell cultures (Figure 1A).
Activated CD4
+ T cells co-expressed LT-a1b2 with other T cell
activation markers CD25 and CD45RO (Figure 1B, C). It has
been previously reported that Th1, Th0 and Th17 subsets express
the highest level of LT-a, compared to Th2 that only express low
transient levels [10,11]. LT-a1b2 was also expressed on the surface
of activated memory CD8
+ T cells; however, expression was lower
than that observed on CD4
+ T cells (Figure 1 D, E). On non-T cell
populations, LT-a1b2 was expressed on B cells stimulated with
anti-IgM and BAFF (Figure 1F), but not on LPS-stimulated
monocytes (Figure 1G). These data confirm and extend previous
studies reporting on the expression pattern of LT-a1b2o n
immune cell subsets [10,11,12,13].
To determine whether LT expression is induced in vivo on
immune cell subsets in the xenogeneic Hu-SCID model of GVHD
[17], unfractionated CFSE-labeled human PBMCs were trans-
ferred intrasplenically into SCID recipient mice, and cellular
expression of LT examined daily by flow cytometry. We first
examined the presence and expansion of immune cell subsets in
the early days of engraftment. Cells were readily detected 2 days
post-transfer, and T and B cells were proliferating by day 3, as
determined by CFSE dilution (Figure 2A–C). On day 2, LT-a was
already expressed on 10% of total human donor lymphocytes
(Figure 2D) and the majority of these were CD4
+ T cells
(Figure 2E–G). We were unable to detect any significant levels
of soluble serum LT-a3 in these animals. As cells proliferated,
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33106Figure 1. LT expression on human immune cell populations. Human CD4
+ T cell expression of LT. A. Sorted CD4
+ T cells were labeled with
CFSE and proliferation and LT expression was monitored at indicated time points following stimulation with anti-CD3 and anti-CD28. B, C. Co-
expression of LT with T cell activation markers CD25 (B) or CD45RO (C) on CD4
+ gated cells. D, E. CD8
+ T cell expression of LT. Co-expression of LT
with CD25 (D) or CD45RO (E) on CD8
+ gated cells. For CD4
+ and CD8
+ T cell activation, PBMCs were stimulated with anti-CD3 and anti-CD28 mAbs for
2 days. F. Human B cell expression of LT. B cells were stimulated with anti-IgM and BAFF for two days, then LT expression determined on CD19
+ B
cells with CD69 as a marker for activation. G. Human monocyte expression of LT. CD14
+ monocytes were stimulated with LPS, with activation status
assessed on the basis of HLA-DR up-regulation.
doi:10.1371/journal.pone.0033106.g001
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+ and CD8
+ T cells maintained surface LT-a expression while
surface LT-a was upregulated on B cells (Figure 2E–G, Figure S1).
Overall, human PBMCs express surface LT-a soon after transfer
and activation in SCID mice.
Generation and properties of humanized depleting anti-
LT-a mAb
We have previously shown that depletion of LT-expressing cells
ameliorated disease in a number of inflammatory and autoim-
Figure 2. Expansion and expression of surface LT on human lymphocytes following transfer into SCID animals. CFSE-labeled human
PBMCs were transferred into SCID mice via intrasplenic injection, then proliferation (A–C) or surface LT expression (D–G) was determined by flow
cytometry. At indicated time points after transfer, spleen cells were harvested and human lymphocyte populations were identified on the basis of
CFSE and specific cell marker staining. Proliferation of CD4
+ T cells (A), CD8
+ T cells (B) and CD19
+ B cells (C). Surface LT expression on CFSE-labeled
bulk transferred human PBMCs (D), or CFSE
+ gated CD4
+ T cells (E), CD8
+ T cells (F) and CD19
+ B cells (G). In each experiment, 2–3 spleens were
pooled to provide sufficient cell numbers for data collection. Data are representative of staining for 1 pool out of 3 per experiment. A minimum of 3
experiments were performed for each cell type.
doi:10.1371/journal.pone.0033106.g002
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[10]. To determine whether depletion of LT-expressing cells in the
xenogeneic Hu-SCID model of GVHD would also achieve
therapeutic benefit, we generated a fully humanized anti-LT-a
antibody, designated MLTA3698A, selected for its ability to bind
LT-a in its different trimeric forms and to mediate depletion of
LT-a-expressing cells.
Anti-LT-a MLTA3698A was derived from a mouse anti-human
LT-a hybridoma mAb, fully humanized after fusing respective VL
and VH domains to the constant domains of human kappa L chain
and human IgG1 H chain, and then affinity matured [18,19,20].
The ability of MLTA3698A to bind to LT-a3 and LT-a1b2 was
confirmed by surface plasmon resonance. Kinetic affinity analysis
showed that MLTA3698A bound to LT-a3 and LT-a1b2 with
affinity constants of 0.4 nM (ka=1.9610
5 M
21 s
21 and
kd=7.9610
25 s
21) and 8.7 nM (ka=2.7610
4 M
21 s
21 and
kd=2.4610
24 s
21), respectively. In ELISA assays, MLTA3698A
bound to LT-a1b2 with an EC50 value of 42 pM, comparable to
that of LT-bR.Ig (EC50=48 pM), and bound LT-a3 with an EC50
of 69 pM, similar to TNFRII.Ig (EC50=133 pM) (Figure 3A, B).
Figure 3. Binding, blocking and depleting properties of anti-LT-a mAb. A. Anti-LT-a MLTA3698A (filled circles) LT-bR.Ig (open squares) and
TNFRII.Ig (open triangles) binding to LT-a1b2 in ELISA binding assays. B. ELISA binding to LT-a3. C. Blockade of LT-bR.Fc binding to LT-a1b2 in ELISA
competition assays with anti-LT-a MLTA3698A (filled circles), LT-bR.Ig (open squares) or TNFRII.Ig (open triangles). D. Blockade of TNFRII.Fc binding to
LT-a3 in ELISA competition assays. ADCC activity of anti-LT-a mAb against LT-expressing cells. LT expression on 293-hLT-ab cells (E) and activated
human CD4
+ T cells (F) was detected using anti-LT-a MLTA3698A (dark gray shaded histograms), anti-LT-a-FcMT mAb (solid line). Isotype control
antibody staining is indicated by light-shaded histograms. Data are representative of at least five experiments. ADCC activity against 293-hLT-ab (G)
or activated CD4
+ T cell (H) targets mediated by MLTA3698A (filled circles) or anti-LT-a-FcMT(open circles). Isotype control mAb is indicated by open
squares. Data are representative of three experiments.
doi:10.1371/journal.pone.0033106.g003
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not bind LT-a1b2, as expected. Furthermore, MLTA3698A
blocked binding of LT-bR.Ig to LT-a1b2 and TNFRII.Ig to LT-
a3 in a competitive dose-dependent manner (Figure 3C, 3D).
MLTA3698A blocked LT-bR.Ig binding with an IC50 value of
0.31 nM, comparable to LT-bR.Ig’s ability to block itself
(IC50=0.1 nM). Similarly, anti-LT-a blocked TNFRII.Ig binding
with an IC50 value of 0.29 nM, comparable to TNFRII.Ig’s ability
to block itself (IC50=0.83 nM).
Critical for the mechanism of action of anti-LT-a in the GVHD
model, we verified that MLTA3698A was functionally capable of
depleting LT-a-expressing cells in ADCC assays. To control for
FccR-mediated depletion, a Fc mutant version of the wild-type
anti-LT-a MLTA3698A (anti-LT-a-FcMT) was generated that
lacks the ability to bind Fcc receptors [10,21]. Both anti-LT-a and
anti-LT-a-FcMT mAbs bound surface LT-a1b2 comparably as
determined by flow cytometry on either 293 cells stably transfected
with LT-a and LT-b (293-hLT-ab cells) or activated human CD4
+
T cells (Figure 3E, F). In in vitro ADCC assays performed using
293-hLT-ab target cells, anti-LT-a elicited dose-dependent
cytotoxicity whereas the effectorless anti-LT-a-FcMT mAb was
unable to mediate cell killing (Figure 3G). Anti-LT-a had no effect
on non-transfected 293 cells alone (data not shown). To extend this
observation to primary immune cells, activated human CD4
+ T
cells were used as targets and were similarly killed in a dose-
dependent manner with anti-LT-a but not with anti-LT-a-FcMT
(Figure 3H). Thus, MLTA3698A is a depleting mAb that
specifically binds soluble and surface expressed LT-a and has
the capacity to mediate ADCC via Fcc receptor-dependent
mechanisms.
Anti-LT-a mAb depletes LT-a-expressing cells in vivo
We then determined whether the MLTA3698A mAb could
deplete LT-a-expressing human immune cells in vivo using the Hu-
SCID GVHD model. SCID mice engrafted with human CFSE-
labeled PBMC by intrasplenic injection were treated one day post-
transfer with either wild-type anti-LT-a and anti-LT-a-FcMT
mAb or human IgG1 isotype control. Spleens were harvested on
the following day (day 2 post-transfer) and the percentage of total
transferred cells expressing LT determined by flow cytometry
(Figure 4). Mice treated with anti-LT-a had a 3-fold decrease in
total LT-a-expressing cells compared to anti-LT-a-FcMT and
isotype control mAb treated animals (Figure 4A). Further
characterization of CD4
+, CD8
+, and CD19
+ immune cell subsets
showed that the decrease observed with anti-LT-a was reflected in
all these subsets (Figure 4B–D). After one day of treatment with
anti-LT-a, the frequencies of CD4
+ T cells, CD8
+ T cells and B
cells were decreased 80%, 60% and 35% respectively. The low
frequency of CD4
+ T cells was also reflected in diminished
expansion of CD4
+ T cells, as evidenced by the paucity of CFSE-
diluted proliferating cells, in the anti-LT-a treatment group at day
4 post-transfer (Figure S2). Cumulatively, anti-LT-a-mediated
depletion was demonstrated to require FccR-dependent pathways
and target T cells and B cells expressing surface LT-a in vivo.
A depleting anti-LT-a mAb inhibits human lymphocyte-
mediated GVHD
Since anti-LT-a mAb anti-LT-a depleted LT-a-expressing
immune cells in vivo, we tested whether this mechanism would
provide efficacy in a standard survival study in this Hu-SCID
GVHD model. SCID mice were engrafted intravenously with
unlabeled human PBMC, and cohorts treated twice-weekly with
i.p. injections of isotype control, CTLA4.Ig therapeutic positive
control or experimental anti-LT-a mAbs, beginning on the day of
transfer, for 28 days. Isotype control-treated SCID mice
succumbed to fatal GVHD-like syndrome within 17 days with a
mean (6 SEM) survival of 14.561.6 days as expected (Figure 5).
Mice treated with anti-LT-a had significantly prolonged survival
(mean survival of 23.662.3 days) compared to the isotype control
group (log rank, p,0.01). The beneficial survival effect of anti-LT-
a was similar to that observed with CTLA-4.Ig treatment, where
mean survival was 26.361.7 days, resulting in 12 days prolonged
survival compared to the isotype group (log rank, p,0.001). Anti-
LT-a-FcMT did not delay mortality, with mean survival of
15.862.0 days, indicating that FccR-mediated killing of LT-a-
expressing cells was a requisite part of the anti-LT-a-driven
survival.
Discussion
We report that targeting subsets of activated immune cells
expressing surface LT-a for depletion using an humanized anti-
LT-a specific depleting antibody resulted in prolonged survival in
xenogeneic Hu-SCID model of GVHD. LT-a exists as a soluble
homotrimer or at the cell surface complexed in a heterotrimer with
LT-b. Surface expression of LT-a1b2 is transiently upregulated on
subsets of activated T and B cells (shown here and [10]). We
previously demonstrated that a depleting mouse anti-LT-a mAb
provided therapeutic efficacy in a number of mouse inflammatory
and autoimmune models. In a mouse model of arthritis, mouse
anti-LT-a efficacy was attributed to depletion of Th1 and Th17
cells, T cell subsets that express LT-a and are the pathogenic
drivers of disease. Conversely, Th2 cells do not express abundant
surface LT-a and, not surprisingly, anti-LT-a had no effect in a
Th2-driven model of asthma. We extend these findings to the
human immune system by using the Hu-SCID GVHD model.
Analyses of LT expression on specific immune cell subsets revealed
that LT expression was induced on human CD4
+ and CD8
+ T
cells and B cells soon after transplantation into recipient mice, and
that treatment with fully humanized depleting anti-LT-a mAb
MLTA3698A significantly reduced the frequency of these
activated effector cells within one day of administration. The
elimination of these potentially pathogenic mediators results in
prolonged survival of transplant recipients.
In humans, allogeneic hematopoietic stem cell transplantation is
an effective therapy for a number of hematological conditions.
While conditioning regimens that include radiation and chemo-
therapy enable engraftment, a significant number of patients
develop donor T cell-mediated GVHD, a major cause of
morbidity and mortality. It is well documented that donor CD4
+
and CD8
+ T cells are the primary mediators of GVHD, resulting
from their activation in response to alloantigen presentation by
host APC. B cells may also play a role in GVHD pathology, with
incidence of acute GVHD mortality correlated with higher
numbers of B cells in the apheresis product [22], higher BAFF
levels and increased numbers of activated memory B cells
associated with chronic GVHD [7]. As such, a number of
therapeutic approaches employing mAbs directed against cellular
surface markers have been tested in the clinic as salvage treatments
in steroid refractory/non-responsive GVHD. However, clinical
efficacy has been limited by increased incidence of graft failure,
leukemia relapse, and susceptibility to post-transplant infection
[3,8]. This may be due to the nonspecific nature of existing mAbs
targeting T cells. For example, OKT3 and visilizumab (CD3)
broadly target all T cells in a ‘‘pan’’ manner, not discriminating
between T cells that are alloreactive and those that are
nonalloreactive [23,24]. Alemtuzumab is more promiscuous,
targeting CD52, an antigen expressed not only by T cells, but
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33106Figure 4. LT-a-specific mAb depletes LT-expressing human lymphocytes in Hu-SCID GVHD model. Spleens were harvested from SCID
mice two days following intrasplenic injection of human PBMCs, after one day treatment with anti-LT-a MLTA3698A, anti-LT-a-FcMT or isotype
control mAb. A. LT staining on total CFSE-labeled transferred cells and enumeration of percentage of total human cells expressing surface LT. B–D.L T
expression and quantitation of mAb treatment effects on specific human lymphocyte populations. Spleen cells were gated on CD4
+ cells (B), CD8
+
cells (C) or CD19
+ cells (D). In each experiment, 2–3 spleens were pooled to provide sufficient cell numbers for data collection. Data show staining for
1 pool out of 3 per experiment, and are representative of a minimum of 2 experiments for each cell type.
doi:10.1371/journal.pone.0033106.g004
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and eosinophils [25]. Daclizumab, basiliximab and denileukin-
difitox target CD25 expressed on activated T cells, and to a lesser
extent on resting T cells. However, CD25 is also expressed by
CD4
+ regulatory T cells, which are important for inducing
tolerance that preserves the graft-versus-leukemia effect following
transplantation [26]. Alefacept recognizes CD2, and selectively
targets effector memory T cells, which may result in impairment of
memory responses against infections [27,28]. AXL-CBL is a mAb
that attempts to eliminate those immune cells directly involved in
GVHD pathology, targeting CD147 that is highly expressed on
activated T and B cells as well as monocytes, macrophages and
dendritic cells [29,30].
The success of these various therapeutic approaches as salvage
treatments in GVHD, despite the aforementioned limitations
associated with side effects, primarily susceptibility to infection,
prompted us to search for cell surface molecules expressed on
those cell populations involved in GVHD pathogenesis that are
amenable for targeted depletion. As an additional criterion, we
sought to identify surface molecules upregulated upon activation,
rather than those constitutively expressed, as this would allow for
targeting of the relevant cell types actively involved in mediating
disease, rather than ‘‘pan’’ depletion of all cells including those
that are naı ¨ve or quiescent. The depleting anti-LT-a mAb
described in this report eliminates those cells expressing surface
LTa1b2. LT expression on human T cells and B cells is induced
soon after transfer into SCID recipient mice, and expression is
maintained predominantly on activated, proliferating cells.
As LTa1b2 appears to selectively and transiently mark activated
T and B lymphocytes, we tested whether anti-human LTa mAb
had therapeutic impact in the chimeric Hu-SCID model of
GVHD. This model of GVHD requires human CD4
+ T cells [17]
and allows for ADCC lysis of human target cells in vivo due to the
presence of functional human NK cells [31]. Mice treated with
depleting anti-LT-a had significantly prolonged survival compared
isotype control Ab-treated animals. No protective effect was seen
with a Fc-effectorless mutant anti-LTa Ab, demonstrating that
efficacy could be attributed to depletion of targeted cells. The
depleting mechanism of action was supported by significant
reductions in frequencies of LT-expressing CD4
+ and CD8
+ T
cells as well as B cells as early as two days after treatment. The
physiological consequences of depletion of CD8
+ T cells and B
cells on disease outcome in the Hu-SCID model are unclear as
others have shown that depletion of these cells did not prevent or
delay development of GVHD in a similar xenogeneic model [32].
Thus, while the Hu-SCID model may have pathological
differences from human disease, anti-LT-a mAb may have the
potential to remove other immune components contributing to
GVHD in human patients.
Our data provide compelling evidence that targeted depletion of
recently activated, pathogenic immune effector cells with anti-LT-a
mAb has promise as a therapeutic strategy for prevention of
GVHD. This data complements our studies using mouse surrogate
reagents to deplete LT-a-expressing cells and achieve therapeutic
benefit in various animal models of autoimmune disease, including
RA and EAE [10]. Anti-LT-a mAb eliminated alloreactive GVHD
mediators by depletion in HuSCID mice, and thus represents a
potential new therapy for the treatment of GVHD. Anti-LT-a may
also have wider applications in treatment of other T cell- and/or B
cell-mediated diseases, including autoimmune disease.
Supporting Information
Figure S1 Expression of surface LT on human lymphocyte
populations following transfer into SCID animals. Proliferation
and surface LT expression on CFSE-labeled human CD4
+ T cells
(A), CD8
+ T cells (B), or CD19
+ B cells (C). CFSE-labeled human
PBMCs were transferred into SCID mice via intrasplenic
injection. At indicated time points after transfer, spleen cells were
harvested then LT expression on proliferating cells, assessed on the
basis of CFSE dilution, was determined by flow cytometry.
Staining for specific cell markers was used to identify immune cell
populations in CFSE
+ gated cells. In each experiment, 2–3 spleens
were pooled to provide sufficient cell numbers for data collection.
Data are representative of staining for 1 pool out of 3 per
experiment. A minimum of 3 experiments were performed for
each cell type.
(TIF)
Figure 5. Efficacy of anti-LT-a mAb in Hu-SCID model of GVHD. SCID mice were sublethally irradiated, randomized, then immediately treated
with anti-LT-a MLTA3698A (filled circles), anti-LT-a-FcMT (open circles), CTLA-4.Ig (open triangles) or isotype control Ab (open squares). 4 hr after
initial treatment, human PBMC were transferred via i.v. injection. Treatment was continued with twice-weekly dosing throughout the study. Two
independent studies were performed with similar results.
doi:10.1371/journal.pone.0033106.g005
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33106Figure S2 Anti-LT-a mAb reduces frequency of LT-expressing
proliferating human CD4
+ T cells in Hu-SCID GVHD model.
Spleens were harvested from SCID mice four days following
intrasplenic injection of human PBMCs, after three days treatment
with anti-LT-a MLTA3698A, anti-LT-a-FcMT or isotype control
mAb. Cells were gated for CD4
+ T cells, then LT expression was
analyzed on CFSE-labeled transferred cells. Data are representa-
tive of three experiments.
(TIF)
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